Biosimilars are challenging to produce, but progress is being made
Rheumatology Drug Research Should Focus on Particular Groups of Patients
An analysis of risks and benefits of drugs in specific types of patients will help rheumatologists provide better treatment
California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients
A systemic lupus erythematosus (SLE) disease expert emphasizes benefits of hydroxychloroquine, burst of steroid treatments
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
Nanoparticle Medicine Delivery Shows Promise
Researchers treated mouse model of systemic lupus erythematous with mycophenolic acid delivered via nanoparticle. (posted June 18, 2013)
Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis
Small molecule kinase inhibitors, such as JAK inhibitors, provide a novel route for rheumatic disease treatment—and may promote our understanding of the immune system’s complexities
ACR Winter Rheumatology Symposium: New Kinase Inhibitors Show Promise
Toxicity and appropriate targeting are challenges for small molecule researchers
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis
A combination therapy with glucocorticoids may be the gold standard for treating patients with rheumatoid arthritis (RA)
Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?
Long-term, low-dose prednisone at less than 5 mg/day appears tolerable and effective for many patients with rheumatoid arthritis (RA)
- « Previous Page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- …
- 125
- Next Page »